The present invention involves a rapid synthesis of .sup.18 F- FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'- imidazolyl)-2- 0-acetyl-3-0-tosylpropanol, glycerol-1,3-ditosylate-2-0- acetylate, 1-(2'- nitro-1'-imidazolyl)-2,3-0-diacetylate, are also important aspects of the invention.PPA further aspect of the invention is the development of a hydrophilic PET ligand to image tumor hypoxia. Erythrotosyl analogue of 2-nitroimidazone (Ts-ETNIM) was prepared from a mixture of 2-nitromidazole, ditosylthreitol and cesium carbonate at 60. degree. C. for 1 hr. Ts-ETNIM was isolated at 70% yield. [.sup.18 F] fluoroerythronitroimidazole (FETNIM) when prepared from Ts- ETNIM and K. sup.18 F/kryptofix®. The yield for [.sup.18 F]FETNIM was 26-30% (60 min, decay corrected). Results of biodistribution and PET studies indicate that [.sup.18 F]FETNIM has the potential to detect tumor hypoxia and is indicated to be less neurotoxic.
展开▼
机译:本发明涉及18 F-FMISO及其类似物的快速合成。新的前体,例如1-(2'-硝基-1'-咪唑基)-2-0-乙酰基-3-0-甲苯磺酰基丙醇,甘油-1,3-二甲苯磺酸酯-2-0-乙酰基,1-(2'-硝基-1'-咪唑基)-2,3-0-二乙酰基酯也是本发明的重要方面。本发明的另一个方面是开发亲水性PET配体以使肿瘤缺氧成像。由2-硝基咪唑,二甲苯磺基苏糖醇和碳酸铯的混合物在60℃下制备2-硝基咪唑啉类的赤藓糖基类似物(Ts-ETNIM)。 C. 1小时。 Ts-ETNIM的分离率为70%。当由Ts-ETNIM和K.up 18 F / kryptofix?制备时,[18 F]氟代硝基硝基咪唑(FETNIM)。 [18 F] FETNIM的产率为26-30%(60分钟,衰减校正)。生物分布和PET研究的结果表明[18 F] FETNIM具有检测肿瘤缺氧的潜力,并显示出较低的神经毒性。
展开▼